|
Name |
2H-Pyran-2-one
|
Molecular Formula | C5H4O2 | |
IUPAC Name* |
pyran-2-one
|
|
SMILES |
C1=CC(=O)OC=C1
|
|
InChI |
InChI=1S/C5H4O2/c6-5-3-1-2-4-7-5/h1-4H
|
|
InChIKey |
ZPSJGADGUYYRKE-UHFFFAOYSA-N
|
|
Synonyms |
2H-Pyran-2-one; alpha-Pyrone; 504-31-4; pyran-2-one; Pyranone; 2-Pyranone; 2-Pyrone; Coumalin; Pyrone; a-pyrone; .alpha.-Pyrone; 2-oxo-2H-pyran; CHEMBL1934663; CHEBI:37965; 8WW45I202V; oxidopyrylium; UNII-8WW45I202V; EINECS 207-990-5; 2H-Pyrane-2-one; 1,2-Pyrone; 2H-Pyran, 2-oxo-; 2H-Pyran-2-one, 90%; DTXSID50198441; ZINC1846601; BDBM50360796; GEO-04164; MFCD00006639; CS-W013734; AS-56552; DB-051773; FT-0622198; P1183; 2H-Pyran-2-one, technical, >=90% (GC); 5-hydroxy-2,4-pentadienoic acid delta-lactone; F16388; 5-hydroxy-2,4-pentadienoic acid delta -lactone; A828125; Q209475; 2,4-Pentadienoic acid, 5-hydroxy-, .delta.-lactone
|
|
CAS | 504-31-4 | |
PubChem CID | 68154 | |
ChEMBL ID | CHEMBL1934663 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 96.08 | ALogp: | 0.8 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 7 | QED Weighted: | 0.483 |
Caco-2 Permeability: | -4.308 | MDCK Permeability: | 0.00003240 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.37 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.655 |
30% Bioavailability (F30%): | 0.261 |
Blood-Brain-Barrier Penetration (BBB): | 0.36 | Plasma Protein Binding (PPB): | 72.93% |
Volume Distribution (VD): | 1.079 | Fu: | 40.30% |
CYP1A2-inhibitor: | 0.741 | CYP1A2-substrate: | 0.511 |
CYP2C19-inhibitor: | 0.135 | CYP2C19-substrate: | 0.09 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.113 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.408 |
CYP3A4-inhibitor: | 0.007 | CYP3A4-substrate: | 0.227 |
Clearance (CL): | 10.055 | Half-life (T1/2): | 0.822 |
hERG Blockers: | 0.141 | Human Hepatotoxicity (H-HT): | 0.081 |
Drug-inuced Liver Injury (DILI): | 0.214 | AMES Toxicity: | 0.068 |
Rat Oral Acute Toxicity: | 0.867 | Maximum Recommended Daily Dose: | 0.02 |
Skin Sensitization: | 0.209 | Carcinogencity: | 0.874 |
Eye Corrosion: | 0.989 | Eye Irritation: | 0.995 |
Respiratory Toxicity: | 0.883 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000190 | 0.379 | D0X9RY | 0.286 | ||||
ENC000675 | 0.368 | D07HBX | 0.270 | ||||
ENC000480 | 0.355 | D0D5GG | 0.267 | ||||
ENC000162 | 0.355 | D05OIS | 0.265 | ||||
ENC000025 | 0.333 | D03GET | 0.244 | ||||
ENC000189 | 0.333 | D01ZJK | 0.244 | ||||
ENC000243 | 0.333 | D06DLI | 0.239 | ||||
ENC000681 | 0.324 | D0R1CR | 0.233 | ||||
ENC001133 | 0.324 | D05BMG | 0.231 | ||||
ENC002806 | 0.317 | D0T3LF | 0.231 |